These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 36514019)

  • 1. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial.
    Podolanczuk AJ; Kim JS; Cooper CB; Lasky JA; Murray S; Oldham JM; Raghu G; Flaherty KR; Spino C; Noth I; Martinez FJ;
    BMC Pulm Med; 2022 Dec; 22(1):475. PubMed ID: 36514019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.
    Oldham JM; Ma SF; Martinez FJ; Anstrom KJ; Raghu G; Schwartz DA; Valenzi E; Witt L; Lee C; Vij R; Huang Y; Strek ME; Noth I;
    Am J Respir Crit Care Med; 2015 Dec; 192(12):1475-82. PubMed ID: 26331942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial.
    Hammond M; Clark AB; Cahn AP; Chilvers ER; Fraser WD; Livermore DM; Maher TM; Parfrey H; Swart AM; Stirling S; Thickett D; Whyte M; Wilson A
    Trials; 2018 Feb; 19(1):89. PubMed ID: 29402332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Behr J; Bendstrup E; Crestani B; Günther A; Olschewski H; Sköld CM; Wells A; Wuyts W; Koschel D; Kreuter M; Wallaert B; Lin CY; Beck J; Albera C
    Lancet Respir Med; 2016 Jun; 4(6):445-53. PubMed ID: 27161257
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP).
    Naccache JM; Montil M; Cadranel J; Cachanado M; Cottin V; Crestani B; Valeyre D; Wallaert B; Simon T; Nunes H
    BMC Pulm Med; 2019 Apr; 19(1):75. PubMed ID: 30971235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and rationale of a multi-center, pragmatic, open-label randomized trial of antimicrobial therapy - the study of clinical efficacy of antimicrobial therapy strategy using pragmatic design in Idiopathic Pulmonary Fibrosis (CleanUP-IPF) clinical trial.
    Anstrom KJ; Noth I; Flaherty KR; Edwards RH; Albright J; Baucom A; Brooks M; Clark AB; Clausen ES; Durheim MT; Kim DY; Kirchner J; Oldham JM; Snyder LD; Wilson AM; Wisniewski SR; Yow E; Martinez FJ;
    Respir Res; 2020 Mar; 21(1):68. PubMed ID: 32164673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis.
    Homma S; Azuma A; Taniguchi H; Ogura T; Mochiduki Y; Sugiyama Y; Nakata K; Yoshimura K; Takeuchi M; Kudoh S;
    Respirology; 2012 Apr; 17(3):467-77. PubMed ID: 22257422
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of the INPULSIS™ trials: two phase 3 trials of nintedanib in patients with idiopathic pulmonary fibrosis.
    Richeldi L; Cottin V; Flaherty KR; Kolb M; Inoue Y; Raghu G; Taniguchi H; Hansell DM; Nicholson AG; Le Maulf F; Stowasser S; Collard HR
    Respir Med; 2014 Jul; 108(7):1023-30. PubMed ID: 24834811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial.
    Richeldi L; Schiffman C; Behr J; Inoue Y; Corte TJ; Cottin V; Jenkins RG; Nathan SD; Raghu G; Walsh SLF; Jayia PK; Kamath N; Martinez FJ
    Am J Respir Crit Care Med; 2024 May; 209(9):1132-1140. PubMed ID: 38354066
    [No Abstract]   [Full Text] [Related]  

  • 11. Double-Blind Randomized Trial of Pirfenidone in Chinese Idiopathic Pulmonary Fibrosis Patients.
    Huang H; Dai HP; Kang J; Chen BY; Sun TY; Xu ZJ
    Medicine (Baltimore); 2015 Oct; 94(42):e1600. PubMed ID: 26496265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
    Maher TM; Ford P; Brown KK; Costabel U; Cottin V; Danoff SK; Groenveld I; Helmer E; Jenkins RG; Milner J; Molenberghs G; Penninckx B; Randall MJ; Van Den Blink B; Fieuw A; Vandenrijn C; Rocak S; Seghers I; Shao L; Taneja A; Jentsch G; Watkins TR; Wuyts WA; Kreuter M; Verbruggen N; Prasad N; Wijsenbeek MS;
    JAMA; 2023 May; 329(18):1567-1578. PubMed ID: 37159034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.
    Behr J; Demedts M; Buhl R; Costabel U; Dekhuijzen RP; Jansen HM; MacNee W; Thomeer M; Wallaert B; Laurent F; Nicholson AG; Verbeken EK; Verschakelen J; Flower CD; Petruzzelli S; De Vuyst P; van den Bosch JM; Rodriguez-Becerra E; Lankhorst I; Sardina M; Boissard G;
    Respir Res; 2009 Oct; 10(1):101. PubMed ID: 19860915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2).
    Maher TM; Kreuter M; Lederer DJ; Brown KK; Wuyts W; Verbruggen N; Stutvoet S; Fieuw A; Ford P; Abi-Saab W; Wijsenbeek M
    BMJ Open Respir Res; 2019; 6(1):e000422. PubMed ID: 31179008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Telomere Length and Use of Immunosuppressive Medications in Idiopathic Pulmonary Fibrosis.
    Newton CA; Zhang D; Oldham JM; Kozlitina J; Ma SF; Martinez FJ; Raghu G; Noth I; Garcia CK
    Am J Respir Crit Care Med; 2019 Aug; 200(3):336-347. PubMed ID: 30566847
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
    Raghu G; van den Blink B; Hamblin MJ; Brown AW; Golden JA; Ho LA; Wijsenbeek MS; Vasakova M; Pesci A; Antin-Ozerkis DE; Meyer KC; Kreuter M; Santin-Janin H; Mulder GJ; Bartholmai B; Gupta R; Richeldi L
    JAMA; 2018 Jun; 319(22):2299-2307. PubMed ID: 29800034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-acetylcysteine exposure is associated with improved survival in anti-nuclear antibody seropositive patients with usual interstitial pneumonia.
    Oldham JM; Witt LJ; Adegunsoye A; Chung JH; Lee C; Hsu S; Chen LW; Husain A; Montner S; Vij R; Strek ME; Noth I
    BMC Pulm Med; 2018 Feb; 18(1):30. PubMed ID: 29422061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
    ; Raghu G; Anstrom KJ; King TE; Lasky JA; Martinez FJ
    N Engl J Med; 2012 May; 366(21):1968-77. PubMed ID: 22607134
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.